vs
Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
BridgeBio Pharma, Inc. is the larger business by last-quarter revenue ($154.2M vs $129.7M, roughly 1.2× Travere Therapeutics, Inc.). On growth, BridgeBio Pharma, Inc. posted the faster year-over-year revenue change (2521.2% vs 73.4%).
Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
BBIO vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $154.2M | $129.7M |
| Net Profit | $-194.6M | — |
| Gross Margin | 94.7% | 98.0% |
| Operating Margin | -90.5% | -25.0% |
| Net Margin | -126.2% | — |
| Revenue YoY | 2521.2% | 73.4% |
| Net Profit YoY | 27.2% | — |
| EPS (diluted) | $-1.00 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $154.2M | $129.7M | ||
| Q3 25 | $120.7M | $164.9M | ||
| Q2 25 | $110.6M | $114.4M | ||
| Q1 25 | $116.6M | $81.7M | ||
| Q4 24 | — | $74.8M | ||
| Q3 24 | — | $62.9M | ||
| Q2 24 | — | $54.1M | ||
| Q1 24 | $211.1M | $41.4M |
| Q4 25 | $-194.6M | — | ||
| Q3 25 | $-184.9M | $25.7M | ||
| Q2 25 | $-183.8M | $-12.8M | ||
| Q1 25 | $-169.6M | $-41.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-54.8M | ||
| Q2 24 | — | $-70.4M | ||
| Q1 24 | $-36.2M | $-136.1M |
| Q4 25 | 94.7% | 98.0% | ||
| Q3 25 | 94.6% | 99.0% | ||
| Q2 25 | 96.7% | 98.7% | ||
| Q1 25 | 97.7% | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | 99.7% | 96.4% |
| Q4 25 | -90.5% | -25.0% | ||
| Q3 25 | -120.3% | 15.1% | ||
| Q2 25 | -121.4% | -11.1% | ||
| Q1 25 | -89.5% | -52.2% | ||
| Q4 24 | — | -81.2% | ||
| Q3 24 | — | -89.3% | ||
| Q2 24 | — | -125.1% | ||
| Q1 24 | 0.2% | -336.5% |
| Q4 25 | -126.2% | — | ||
| Q3 25 | -153.2% | 15.6% | ||
| Q2 25 | -166.2% | -11.1% | ||
| Q1 25 | -145.4% | -50.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -87.1% | ||
| Q2 24 | — | -130.1% | ||
| Q1 24 | -17.1% | -328.9% |
| Q4 25 | $-1.00 | $0.04 | ||
| Q3 25 | $-0.95 | $0.28 | ||
| Q2 25 | $-0.95 | $-0.14 | ||
| Q1 25 | $-0.88 | $-0.47 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.70 | ||
| Q2 24 | — | $-0.91 | ||
| Q1 24 | $-0.20 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $570.1M | $93.0M |
| Total DebtLower is stronger | $2.0B | — |
| Stockholders' EquityBook value | $-2.1B | $114.8M |
| Total Assets | $936.0M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $570.1M | $93.0M | ||
| Q3 25 | $643.0M | $110.9M | ||
| Q2 25 | $756.9M | $75.2M | ||
| Q1 25 | $540.6M | $61.9M | ||
| Q4 24 | — | $58.5M | ||
| Q3 24 | — | $36.4M | ||
| Q2 24 | — | $32.3M | ||
| Q1 24 | $519.7M | $43.3M |
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-2.1B | $114.8M | ||
| Q3 25 | $-1.9B | $73.6M | ||
| Q2 25 | $-1.8B | $32.7M | ||
| Q1 25 | $-1.6B | $32.8M | ||
| Q4 24 | — | $59.1M | ||
| Q3 24 | — | $-30.5M | ||
| Q2 24 | — | $15.1M | ||
| Q1 24 | $-1.0B | $74.1M |
| Q4 25 | $936.0M | $605.2M | ||
| Q3 25 | $998.3M | $538.6M | ||
| Q2 25 | $1.1B | $555.3M | ||
| Q1 25 | $881.6M | $548.8M | ||
| Q4 24 | — | $594.1M | ||
| Q3 24 | — | $504.4M | ||
| Q2 24 | — | $551.1M | ||
| Q1 24 | $849.3M | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-56.4M | $60.7M |
| Free Cash FlowOCF − Capex | $-56.5M | — |
| FCF MarginFCF / Revenue | -36.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-56.4M | $60.7M | ||
| Q3 25 | $-109.6M | $14.3M | ||
| Q2 25 | $-80.7M | $5.0M | ||
| Q1 25 | $-199.2M | $-42.2M | ||
| Q4 24 | — | $-35.7M | ||
| Q3 24 | — | $-42.5M | ||
| Q2 24 | — | $-40.2M | ||
| Q1 24 | $-219.5M | $-119.0M |
| Q4 25 | $-56.5M | — | ||
| Q3 25 | $-110.0M | $14.2M | ||
| Q2 25 | $-81.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-40.3M | ||
| Q1 24 | $-220.2M | — |
| Q4 25 | -36.6% | — | ||
| Q3 25 | -91.2% | 8.6% | ||
| Q2 25 | -73.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -74.5% | ||
| Q1 24 | -104.3% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.4% | 0.1% | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | 0.3% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BBIO
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
